* Black Diamond Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Black Diamond Therapeutics Inc is for a loss of 43 cents per share.
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 0.2% in the last three months.
* Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $12.00, above its last closing price of $6.59.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.45 -0.47 -0.34 Beat 27
Sep. 30 2023 -0.44 -0.49 -0.45 Beat 7.5
Jun. 30 2023 -0.54 -0.54 -0.52 Beat 3
Mar. 31 2023 -0.61 -0.61 -0.57 Beat 6.2
Dec. -0.63 -0.59 Beat 6
31 2022
Sep. 30 2022 -0.64 -0.64 -0.60 Beat 6.3
Jun. 30 2022 -0.69 -0.68 -0.63 Beat 7.4
Mar. 31 2022 -0.78 -0.75 -0.70 Beat 6.8
This summary was machine generated May 3 at 13:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments